Reduced hepatic inflammation and lipid deposition was demonstrated in T2D-associated liver pathology following a tri-pathway-targeting approach using HM1521, an agent that targets glucagon/GIP/GLP-1Ra in mice and in humans (117, 127). This evidence concerns the gene GIP and type 2 diabetes mellitus.